BACKROUND: Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. METHODS: A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. RESULTS: Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. CONCLUSIONS: EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.

Department of Experimental and Clinical Pharmacology Center for Preclinical Research and Technology Medical University of Warsaw Poland ul Banacha 1b 02 097 Warsaw Poland

Department of Health Economics Centre for Public Health Medical University of Vienna Kinderspitalgasse 15 1 Vienna 1090 Austria

Department of Health Economics Corvinus University of Budapest Fővám tér 8 H 1093 Budapest Hungary

Department of Social Medicine University of Amsterdam Meibergdreef 9 22660 1100 DD Amsterdam The Netherlands

Department of Social Pharmacy and Pharmacoeconomics Faculty of Pharmacy Medical University Sofia Bulgaria

DOBA Business School Prešernova ulica 1 2000 Maribor Slovenia

Doctoral School of Management Corvinus University of Budapest Fővám tér 8 Budapest 1093 Hungary

Institute for Economic Research Kardeljeva ploščad 17 1000 Ljubljana Slovenia

Institute of Rheumatology Na Slupi 4 128 00 Prague Czech Republic

Premium Postdoctoral Research Programme Hungarian Academy of Sciences Nádor u 7 Budapest 1051 Hungary

Zobrazit více v PubMed

Neurology. 1999 Jul 13;53(1):162-6 PubMed

Ann Med. 2001 Jul;33(5):337-43 PubMed

Cerebrovasc Dis. 2004;17(2-3):143-52 PubMed

Nervenarzt. 2004 Oct;75(10):1000-6 PubMed

Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23 PubMed

Ideggyogy Sz. 2008 Jan 30;61(1-2):42-8 PubMed

J Neurol. 2010 Apr;257(4):638-45 PubMed

Ideggyogy Sz. 2010 Jul 30;63(7-8):247-51 PubMed

Qual Life Res. 2011 Dec;20(10):1727-36 PubMed

Clin Neuropharmacol. 2012 Mar-Apr;35(2):73-6 PubMed

Ideggyogy Sz. 2012 Jul 30;65(7-8):249-60 PubMed

Ideggyogy Sz. 2012 Sep 30;65(9-10):316-24 PubMed

J Med Life. 2012 Dec 15;5(4):375-81 PubMed

Psychiatr Pol. 2013 May-Jun;47(3):433-42 PubMed

Ideggyogy Sz. 2013 Jul 30;66(7-8):251-61 PubMed

Patient Relat Outcome Meas. 2013 Oct 23;4:75-85 PubMed

Adv Med Sci. 2014 Mar;59(1):34-8 PubMed

Int J Neurosci. 2015 May;125(5):344-51 PubMed

Parkinsons Dis. 2014;2014:158353 PubMed

Qual Life Res. 2015 Apr;24(4):845-50 PubMed

J Parkinsons Dis. 2014;4(4):687-91 PubMed

Qual Life Res. 2015 Jun;24(6):1555-63 PubMed

Ideggyogy Sz. 2014 Jul 30;67(7-8):245-50 PubMed

Parkinsons Dis. 2015;2015:936865 PubMed

Clin Neurol Neurosurg. 2015 Dec;139:35-40 PubMed

Eur J Neurol. 2015 Oct;22 Suppl 2:28-33 PubMed

Ideggyogy Sz. 2015 Sep 30;68(9-10):325-30 PubMed

Eur J Health Econ. 2016 Apr;17 Suppl 1:19-29 PubMed

Parkinsons Dis. 2016;2016:7951840 PubMed

Ideggyogy Sz. 2016 Mar 30;69(5-6):183-93 PubMed

Qual Life Res. 2016 Nov;25(11):2693-2710 PubMed

Wiad Lek. 2016;69(4):631-636 PubMed

Mult Scler. 2017 Aug;23(2_suppl):41-52 PubMed

Mult Scler. 2017 Aug;23(2_suppl):130-142 PubMed

Mult Scler. 2017 Aug;23(2_suppl):91-103 PubMed

Mult Scler. 2017 Aug;23(2_suppl):17-28 PubMed

Rheumatol Int. 2017 Dec;37(12):1957-1977 PubMed

Health Qual Life Outcomes. 2018 Jan 10;16(1):8 PubMed

Kardiol Pol. 2018;76(5):860-870 PubMed

Value Health Reg Issues. 2014 Sep;4:95-99 PubMed

Qual Life Res. 1995 Jun;4(3):241-8 PubMed

Med Care. 1995 Apr;33(4 Suppl):AS131-44 PubMed